Recombinant human factor VIIa prevents hysterectomy in severe postpartum hemorrhage: single center study
Authors:
- 1 January 2012
- journal article
- clinical trial
- Published by Walter de Gruyter GmbH in Journal of Perinatal Medicine
- Vol. 40 (1) , 43-9
Abstract
To evaluate the effectiveness of human recombinant activated factor VII (rhFVIIa, NovoSeven) in avoiding hysterectomy postpartum in the management of severe postpartum hemorrhage (PPH). We performed a prospective cohort study at our university tertiary care center. Patients with severe post partum hemorrhage (blood loss >2000 mL) and failed medical and uterus-preserving surgical management, were treated with intravenous bolus administration of rhVIIa. Main outcome measures were cessation of bleeding, postpartum hysterectomy and thromboembolic events. In 20/22 patients included, PPH was caused primarily by uterine atony, including 7 (32%) with additional lower genital tract lesion; in two women, it was due to pathologic placentation (placenta increta, 9%). One case of amniotic fluid embolism and one woman with uterine inversion were included. Recombinant hFVIIa was successful in stopping the PPH and in preventing a hysterectomy in 20/22 women (91%). The remaining two patients with persistent bleeding despite rhFVIIa treatment, who underwent postpartum hysterectomy, had placenta increta. No thromboembolic event was noticed. This study describes the largest single center series of rhFVIIa treatment for fertility preservation in severe postpartum hemorrhage published to date. Our data suggest that administration of rhFVIIa is effective in avoiding postpartum hysterectomy after conservative medical and surgical measures have failed. Although randomized studies are lacking, rhFVIIa should be considered as a second-line therapeutic option of life-threatening postpartal bleeding, in particular if preservation of fertility is warranted and hysterectomy is to be avoided.Keywords
This publication has 25 references indexed in Scilit:
- Reply of the Authors: Postpartum hemorrhage: new management?Fertility and Sterility, 2008
- Diagnosis and treatment of peripartum bleedingJournal of Perinatal Medicine, 2008
- An open non‐randomized study of recombinant activated factor VII in major postpartum haemorrhageActa Anaesthesiologica Scandinavica, 2007
- The Hayman technique: a simple method to treat postpartum haemorrhageBJOG: An International Journal of Obstetrics & Gynaecology, 2007
- Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United KingdomAnaesthesia, 2006
- Conservative management of placenta increta with selective arterial embolization preserves future fertility and results in a favorable outcome in subsequent pregnanciesFertility and Sterility, 2006
- Factor VIIa in Puerperal Hemorrhage With Disseminated Intravascular CoagulationObstetrics & Gynecology, 2006
- The use of recombinant factor VIIa in severe postpartum hemorrhageActa Obstetricia et Gynecologica Scandinavica, 2004
- Recombinant Activated Factor VII (rFVIIa): Characterization, Manufacturing, and Clinical DevelopmentSeminars in Thrombosis and Hemostasis, 2001
- Oral misoprostol for third stage of labor: a randomized placebo-controlled trialObstetrics & Gynecology, 1999